Despite SP guidance remains unchanged - No matter the market conditions, they have a highly successful flower business and are selling a product that has proven demand. Unlike many other LPs in the industry, they have not experienced strong downward pricing pressures on their flower.
Let's see if they follow-up on the 19M Q4 before conclusions are drawn. Throw in the EU CBD market and vape/extract sales 2020 still looks to be a good year.
Adding here when I can. GLTA.